Boot A, et al. (2022) Recurrent mutations in topoisomerase IIα cause a previously undescribed mutator phenotype in human cancers. Proc Natl Acad Sci U S A 119(4) PMID:35058360
Stantial N, et al. (2020) Trapped topoisomerase II initiates formation of de novo duplications via the nonhomologous end-joining pathway in yeast. Proc Natl Acad Sci U S A 117(43):26876-26884 PMID:33046655
Sun Y, et al. (2020) A conserved SUMO pathway repairs topoisomerase DNA-protein cross-links by engaging ubiquitin-mediated proteasomal degradation. Sci Adv 6(46) PMID:33188014
Blower TR, et al. (2019) A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents. Nucleic Acids Res 47(15):8163-8179 PMID:31287876
Tombline G, et al. (2017) Effects of an unusual poison identify a lifespan role for Topoisomerase 2 in Saccharomyces cerevisiae. Aging (Albany NY) 9(1):68-97 PMID:28077781
Hasinoff BB, et al. (2012) The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II. Biochem Pharmacol 84(12):1617-26 PMID:23041231
Rogojina AT and Nitiss JL (2008) Isolation and characterization of mAMSA-hypersensitive mutants. Cytotoxicity of Top2 covalent complexes containing DNA single strand breaks. J Biol Chem 283(43):29239-50 PMID:18723844
Stepanov A, et al. (2008) Enhancing drug accumulation in Saccharomyces cerevisiae by repression of pleiotropic drug resistance genes with chimeric transcription repressors. Mol Pharmacol 74(2):423-31 PMID:18469141
He X, et al. (2007) Mutation of a conserved active site residue converts tyrosyl-DNA phosphodiesterase I into a DNA topoisomerase I-dependent poison. J Mol Biol 372(4):1070-1081 PMID:17707402
Malik M, et al. (2006) Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage. Mol Cancer Ther 5(6):1405-14 PMID:16818498
Nitiss KC, et al. (2006) Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage. Proc Natl Acad Sci U S A 103(24):8953-8 PMID:16751265
Vaughn J, et al. (2005) Stability of the topoisomerase II closed clamp conformation may influence DNA-stimulated ATP hydrolysis. J Biol Chem 280(12):11920-9 PMID:15647268
Sabourin M, et al. (2003) Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks. Nucleic Acids Res 31(15):4373-84 PMID:12888496
Khan SI, et al. (2002) Antifungal activity of eupolauridine and its action on DNA topoisomerases. Antimicrob Agents Chemother 46(6):1785-92 PMID:12019091
Strumberg D, et al. (2002) Importance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA cleavage site recognition and quinolone action. Antimicrob Agents Chemother 46(9):2735-46 PMID:12183223
Pourquier P, et al. (2001) Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine. Cancer Res 61(1):53-8 PMID:11196197
Dong J, et al. (2000) A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons. J Biol Chem 275(11):7980-7 PMID:10713116
Strumberg D, et al. (1999) Mutation of a conserved serine residue in a quinolone-resistant type II topoisomerase alters the enzyme-DNA and drug interactions. J Biol Chem 274(11):7292-301 PMID:10066792
Strumberg D, et al. (1999) Molecular analysis of yeast and human type II topoisomerases. Enzyme-DNA and drug interactions. J Biol Chem 274(40):28246-55 PMID:10497180
Wessel I, et al. (1999) Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform. Cancer Res 59(14):3442-50 PMID:10416608
Nitiss JL, et al. (1998) The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II. Biochemistry 37(9):3078-85 PMID:9485461
Sabourin M, et al. (1998) A mutant yeast topoisomerase II (top2G437S) with differential sensitivity to anticancer drugs in the presence and absence of ATP. J Biol Chem 273(44):29086-92 PMID:9786915
Sehested M, et al. (1998) Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Cancer Res 58(7):1460-8 PMID:9537249
Hsiung Y, et al. (1996) Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti-topoisomerase II agents. Cancer Res 56(1):91-9 PMID:8548781
Nitiss JL and Wang JC (1996) Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol Pharmacol 50(5):1095-102 PMID:8913340
Elsea SH, et al. (1995) A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine. J Biol Chem 270(4):1913-20 PMID:7829529
Hsiung Y, et al. (1995) A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors. J Biol Chem 270(35):20359-64 PMID:7657608
Ishida R, et al. (1995) DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae. Cancer Res 55(11):2299-303 PMID:7757979
Liu YX, et al. (1994) Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide. Cancer Res 54(11):2943-51 PMID:8187080
Nitiss JL, et al. (1994) Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine. Mol Pharmacol 46(4):773-7 PMID:7969059
Jannatipour M, et al. (1993) The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine. J Biol Chem 268(25):18586-92 PMID:8395511
Nitiss JL, et al. (1993) A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors. Cancer Res 53(1):89-93 PMID:8380128
Elsea SH, et al. (1992) Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast. J Biol Chem 267(19):13150-3 PMID:1320012
Nitiss JL, et al. (1992) Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res 52(16):4467-72 PMID:1322791